ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Wyden Compared Taxol To AZT; But Experts Note Lack Of Patent

August 9, 1991

Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program

August 27, 1982

Proposed Surveillance Model Aims To Reduce Post-Treatment Pain

April 27, 2012

ASCO Is a Society In Transition, Growth; Major changes over Past Year

May 24, 1996

Velcade Plus Dexamethasone Provides 20% Response In First-Line Treatment

December 29, 2006

NCI Programs: Report Calls for Expansion of Colorectal Cancer Research

April 28, 2000